Keywords
Tobacco harm reduction, heated tobacco, smoke-free, IQOS, use patterns, prevalence, smoking initiation, smoking reinitiation
This article is included in the Global Public Health gateway.
Tobacco harm reduction, heated tobacco, smoke-free, IQOS, use patterns, prevalence, smoking initiation, smoking reinitiation
It is well established that cigarette smoking can lead to numerous negative health outcomes, including premature and preventable death1. The burden of smoking on individual and population health has driven health authorities and regulatory bodies to recommend and implement various tobacco control policies2. Never initiating or quitting smoking are the most direct ways to alleviate the health burden of smoking3. However, strategies aimed at preventing smoking and promoting cessation continue to face numerous challenges, including smokers who are not motivated to quit or who relapse/reinitiate smoking after a period of abstinence2,4,5. While smoking prevalence has declined over the last decades, over 1 billion people globally continue to smoke combustible tobacco products today1,6, and cigarette smoking continues to be responsible for the largest number of preventable deaths worldwide7,8.
To complement tobacco control efforts9, tobacco harm reduction strategies have been introduced around the world10,11. Tobacco harm reduction includes prevention of tobacco or nicotine-containing product (TNP) use initiation and reinitiation2,11,12 while ensuring that adult smokers switch completely from combustible TNPs to less harmful smoke-free (i.e., non-combustible) TNPs13,14.
Unlike cigarettes, which burn tobacco and produce a complex mixture of harmful and potentially harmful constituents (HPHC) through combustion, IQOSTM, a smoke-free heated tobacco product (HTP) developed by Philip Morris International (PMI), heats a specifically engineered tobacco stick (i.e., HEETSTM/HeatSticksTM) to temperatures below the level of combustion15. As a consequence, smokers who switch completely to IQOS use are exposed to much lower levels of HPHCs than those who continue smoking cigarettes16–20.
As part of PMI’s commitment to a smoke-free future, IQOSTM was introduced in Japan in 2014 and is now available in more than 70 countries worldwide, with an estimated 21 million adult users globally21. The availability and demand for IQOS as an alternative to cigarettes has raised the need to monitor IQOS use prevalence and use patterns with the aim of informing public health authorities locally and worldwide. Such findings will further enable regulators to delineate the role of IQOS in harm reduction as a viable substitute for cigarettes2,22.
Building on the reporting of Afolalu et al.23, the aim of the current study was to analyze the temporal trends in TNP use in nationally representative samples of the Japanese general adult population (JGAP) and, separately, in samples of Japanese adult IQOS users (JAIQOS) from PMI’s adult IQOS owner database in Japan across three recent years (2016/2017, 2017/2018, and 2018/2019).
Cross-sectional surveys in representative samples of the Japanese general adult population (JGAP) and, separately, in samples of Japanese adult IQOSTM users (JAIQOS) registered in the IQOS owner database of Philip Morris International (PMI)’s affiliate in Japan were initiated in December 2016 and repeated annually over three full calendar years from 2016/2017 to 2018/2019 (Figure 1). Considering that IQOS was relatively new on the Japanese TNP market in 2016, the IQOS use prevalence in the JGAP was expected to be low. Therefore, additional surveys among JAIQOS were conducted alongside the JGAP surveys to obtain reliable estimates of IQOS use patterns among Japanese adult IQOS users23.
Abbreviations: ICF, informed consent form; JAIQOS, sample of adult Japanese IQOS users from PMI’s IQOS™ owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International.
Study participants
To be included in the JGAP or JAIQOS samples, individuals had to be of legal age for purchasing TNPs in Japan (i.e., ≥20 years), current residents of Japan, and fluent in Japanese. Those included in the JAIQOS samples also had to have used >100 HEETSTM/HeatSticksTM in their lifetime24, be a current user of IQOS with HEETS/HeatSticks, have access to the internet, and not be currently employed by PMI or its affiliates.
JGAP — Sampling, sample size, and survey mode
The JGAP samples were obtained via a syndicated (Omnibus) survey overseen and coordinated by Ipsos UK Ltd (London, UK). The fieldwork provider in Japan was Central Research Services Inc (Tokyo, Japan). The Omnibus surveys employed a three-stage stratified proportional sampling strategy that included the whole country. In stage 1, sampling points in the 12 Japanese administrative regions were allocated on the basis of their share of the population25. Households within each sampling point were identified in Stage 2 by using an electronic residential map, from which about 40 households were randomly selected. In the final stage 3, participants who met the inclusion criteria were selected from within the sampled households. Within each sampling point, quotas on age and sex were set to ensure the representativeness of the Japanese population.
The annual JGAP sampling consisted of four approximately equal-sized waves spaced throughout each study year to account for potential seasonal differences (Figure 2). A sample size of 5,000 participants per year was sufficient to estimate an IQOSTM use prevalence of 5.0% with 95% confidence and a precision of ±0.6% units. In the third year, six survey waves (7,000 participants) were conducted to increase the sample size and improve the accuracy of the estimates.
Abbreviations: JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International; W, survey wave.
The JGAP surveys were conducted at participants’ homes through in-person face-to-face pen-and-paper interviews. However, to avoid any bias on basis of social desirability of their response regarding their personal TNP use, the participants were handed the “Tobacco Use Prevalence” questionnaire section for self-completion. For completing the Omnibus questionnaires, each participant was given a coupon for JPY 500 (approximately USD 4).
JAIQOS — Sampling, sample size, and survey mode
Upon purchasing an IQOSTM device, users were invited to register in the PMI Japan IQOS owner database, which included about 350,000 adult IQOS owners in July 2017 and reached close to six million in 2019. Considering the demographic age-sex distribution of the database, individuals were randomly selected from the database and invited by email to participate in the survey for each wave.
A sample size of 2,000 participants per year was sufficient to estimate a 50% proportion of exclusive IQOS use with 95% confidence and a precision of ±2.19% units. Each annual IQOS user sample consisted of four approximately equal-sized waves spaced throughout each study year to account for potential seasonal differences (Figure 2), with the aim of recruiting 500 adult participants per wave. The JAIQOS surveys were conducted entirely online through computer-assisted self-interviewing. For completing the online survey, participants were given a gift code valued at JPY 500 (about USD 4). The existing standard TNP use questions are available in the literature.
Survey questionnaires
For the present study, the “Tobacco Use Prevalence” questionnaire was developed on the basis of several existing standard TNP use questions available in the literature to capture information about TNP use; the questionnaire was not specifically validated. In both the JGAP and JAIQOS samples, the same questionnaire was used. However, while for the JGAP samples a pen-and-paper self-completion survey mode was used, for the JAIQOS samples an online mode was applied. The survey questions can be found in the Extended data.
Ethical conduct of the study
All subjects gave informed consent for inclusion in the study prior to participation. The participants of the JGAP samples gave verbal consent that was recorded by the interviewers as part of the Omnibus interviews, while the participants of the JAIQOS samples provided written consent. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and were consistent with Good Epidemiological Practice (GEP)26. The study protocol, including the procedures of providing informed consent, were approved by the Hakata Clinic Institutional Review Board (Reference ID: J-186) in Fukuoka, Japan.
Analytical methods
Analyses were conducted using SAS v9.4 (or higher; SAS Inc., Cary, North Carolina, USA). For both the JGAP and JAIQOS samples, data were analyzed and summarized descriptively for each study year. For participant characteristics and outcome measures, continuous data are presented as mean and standard deviation (SD) or 95% confidence intervals (CI) and categorical data as number and percentage (95% CI) for the total samples and/or stratified by age and sex. Missing data were not included in the statistical analyses.
The following definitions were applied: “Use/never use” of cigarettes or IQOSTM with HEETSTM/HeatSticksTM: having/not having used 100 cigarettes or 100 HEETS/HeatSticks in the lifetime, to differentiate established cigarette or IQOS users from triers or experimenters24. “Current use”: daily or nondaily use of a TNP at the time of the survey. “Exclusive”, “dual”, and “poly” use: current use of only one type, two types, or three or more types of TNPs, respectively. “Initiation”: the time point at which a participant started established use/smoking of a TNP. “Initiation rate”: proportion of initiation in the last 12 months among never TNP users. “Relapse” and “reinitiation”: restarting TNP use following a period of quitting all TNPs for ≤12 months and >12 months, respectively.
Prevalence of current TNP use for overall TNPs or by TNP category (cigarettes, IQOS, e-cigarettes, etc.) was calculated in the JGAP samples. For both JGAP and JAIQOS samples, the following was calculated: response rates, sample characteristics, and patterns of TNP use (JGAP: exclusive, dual, and poly use; JAIQOS: exclusive IQOS use and IQOS use with combustible or smoke-free TNP) as well as frequency (past 30-day use), intensity (average daily consumption), and history (JGAP: initiation, relapse, and reinitiation with IQOS; JAIQOS: previous cigarette smoking history before starting IQOS use) of TNP use.
Regarding survey dispositions and outcome rates (Figure 3), the JGAP samples had a response rate of >30% in each of the three study years (Y1-Y3), which resulted in sample sizes of 4,878, 4,791, and 7,236 for Y1-Y3 of the Omnibus survey, respectively. In the Y1-Y3 JAIQOS samples, response rates of 19.4%, 4.7%, and 2.0% yielded sample sizes of 2,000, 2,044, and 2,013, respectively.
Abbreviations: JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; n1-n3, sample sizes for study years 1–3, respectively; PMI, Philip Morris International.
Sample characteristics
JGAP samples
Overall, the demographic characteristics of the JGAP samples were similar across Y1-Y3 (Table 1) and comparable with those of the Japanese adult population25. The mean (±SD) ages of the Y1-Y3 samples were 53.8 (±17.9), 54.5 (±17.6), and 54.8 (±17.8) years, respectively, and each of the samples included slightly more women (Y1-Y3: 51.9%, 53.3% and 53.2%) than men (Y1-Y3: 48.1%, 46.7%, and 46.8%), mirroring the female skew in the actual Japanese population25.
Japanese population (2016)* (%) | Number (n) and percentage (% [95% CI]) | ||||||
---|---|---|---|---|---|---|---|
Year 1 (2016/2017) | Year 2 (2017/2018) | Year 3 (2018/2019) | |||||
JGAP (N=4,878) | JAIQOS (N=2,000) | JGAP (N=4,791) | JAIQOS (N=2,044) | JGAP (N=7,236) | JAIQOS (N=2,013) | ||
Sex | |||||||
Men | 48.3 | 2,345 48.1 [46.6–49.5] | 1,632 81.6 [79.8–83.3] | 2,238 46.7 [45.2–48.2] | 1,641 80.3 [78.4–82.0] | 3,385 46.8 [45.6–48.0] | 1,609 79.9 [78.1–81.7] |
Women | 51.7 | 2,533 51.9 [50.5–53.4] | 368 18.4 [16.7–20.2] | 2,553 53.3 [51.8–54.8] | 403 19.7 [18.0–21.6] | 3,851 53.2; [52.0–54.4] | 404 20.1 [18.3–21.9] |
Age (years) | |||||||
20–29 | 12 | 528 10.8 [9.9–11. 8] | 420 21.0 [19.2–22.9] | 464 9.7 [8.8–10.6] | 346 16.9 [15.3–18.7] | 704 9.7 [9–10.5] | 330 16.4 [14.8–18.1] |
30–39 | 15.1 | 723 14.8 [13.8–15.9] | 736 36.8 [34.6–39.0] | 668 13.9 [12.9–15.0] | 710 34.7 [32.6–36.9] | 978 13.5 [12.7–14.4] | 710 35.3 [33.1–37.5] |
40–49 | 17.8 | 873 17.9 [16.8–19.1] | 568 28.4 [26.4–30.5] | 886 18.5 [17.4–19.7] | 642 31.4 [29.4–35.5] | 1,336 18.5 [17.5–19.4] | 644 32.0 [29.9–34.1] |
50+ | 55.2 | 2,754 56.5 [55.0–57.9] | 276 13.8 [12.3–15.4] | 2,773 57.9 [56.4–59.3] | 346 16.9 [15.3–18.7] | 4,218 58.3 [57.1–59.5] | 329 16.3 [14.7–18.1] |
Mean [±SD] | - | 53.8 [±17.9] | 38.5 [±9.7] | 54.5 [±17.6] | 39.7 [±10.1] | 54.8 [±17.8] | 39.9 [±9.9] |
Education | |||||||
Junior high school | 8.6 | 454 9.3 [8.5–10.2] | 124 6.2 [5.1–7.4] | 417 8.7 [7.9–9.6] | 139 6.8 [5.7–8.0] | 619 8.6 [7.9–9.3] | 151 7.5 [6.3–8.8] |
High school | 40.1 | 2,395 49.1 [47.6–50.6] | 726 36.3 [34.1–38.5] | 2,433 50.8 [49.3–52.3] | 753 36.8 [34.7–39.0] | 3,603 49.8 [48.6–51] | 744 37.0 [34.8–39.2] |
College/University | 41.8 | 1,980 40.6 [39.2–42.0] | 1,135 56.8 [54.5–59.0] | 1,917 40.0 [38.6–41.5] | 1,114 54.4 [52.3–56.7] | 2,967 41.0 [39.8–42.2] | 1,085 53.9 [51.6–56.1] |
Don’t know/NA | 9.5 | 49 1.0 [0.7–1.4] | 15 0.8 [0.4–1.3] | 24 0.5 [0.3–0.8] | 38 1.9 [1.3–2.6] | 47 0.6 [0.4–0.9] | 33 1.6 [1.1–2.3] |
Occupation | |||||||
Farming/Agriculture/Fishery | - | 80 1.6 [1.3–2.1] | 8 0.4 [0.1–0.8] | 89 1.9 [1.4–2.3] | 15 0.7 [0.4–1.3] | 165 2.3 [1.9–2.7] | 18 0.9 [0.5–1.5] |
Self-employed/Small private business | 12.1 | 538 11.0 [10.1–12.0] | 329 16.5 [14.8–18.2] | 511 10.7 [9.8–11.6] | 347 17.0 [15.3–18.7] | 848 11.7 [10.9–12.5] | 354 17.6 [15.9–19.4] |
Clerical employee | - | 927 19.0 [17.9–20.2] | 284 14.2 [12.6–15.9] | 845 17.6 [16.5–18.8] | 228 11.2 [9.8–12.6] | 1,289 17.8 [16.9–18.8] | 271 13.5 [12–19.4] |
Manual employee | - | 1,063 21.8 [20.6–23.0] | 268 13.4 [11.9–15.0] | 1,094 22.8 [21.6–24.1] | 272 13.3 [11.8–14.9] | 1,560 21.6 [20.6–22.6] | 253 12.6 [11.1–14.1] |
Managing profession | 46.9 | 118 2.4 [2.0–2.9] | 414 20.7 [18.9–22.6] | 108 2.3 [1.8–2.8] | 432 21.1 [19.3–23.0] | 197 2.7 [2.3–3.2] | 398 19.8 [18.0–21.6] |
Housewife | 19.9 | 1,211 24.8 [23.6–26.1] | 84 4.2 [3.3–5.2] | 1,175 24.5 [23.3–25.8] | 115 5.6 [4.6–6.8] | 1,791 24.8 [23.7–25.8] | 95 4.7 [3.8–5.8] |
Student | 2 | 106 2.2 [1.7–2.7] | 37 1.9 [1.3–2.6] | 82 1.7 [1.3–2.2] | 34 1.7 [1.1–2.4] | 160 2.2 [1.8–2.6] | 28 1.4 [0.9–2.1] |
Retired/Unemployed | 19.1 | 835 17.1 [16.0–18.3] | 26 1.3 [0.8–1.9] | 887 18.5 [17.3–19.7] | 69 3.4 [2.6–4.3] | 1,226 16.9 [16–17.9] | 43 2.1 [1.5–2.9] |
Don’t know/NA | - | NA | 550 27.5 [25.5–29.6] | NA | 532 26.0 [24.1–28.0] | NA | 553 27.5 [25.5–29.5] |
Region | |||||||
Chubu | - | 964 19.8 [18.6–21.0] | 310 15.5 [13.9–17.2] | 908 19.0 [17.8–20.1] | 288 14.1 [12.6–15.7] | 964 19.8 [18.6–21.0] | 285 14.2 [12.6–15.8] |
Chugoku | - | 294 6.0 [5.3–6.8] | 94 4.7 [3.8–5.8] | 281 5.9 [5.2–6.6] | 95 4.6 [3.7–5.7] | 294 6.0 [5.3–6.8] | 87 4.3 [3.4–5.4] |
Hokkaido | - | 219 4.5 [3.9–5.2] | 58 2.9 [2.2–3.8] | 214 4.5 [3.8–5.1] | 93 4.5 [3.6–5.6] | 219 4.5 [3.9–5.2] | 93 4.6 [3.7–5.7] |
Kanto | - | 1,585 32.5 [31.1–33.9] | 871 43.6 [41.3–45.8] | 1,610 33.6 [32.2–35.0] | 827 40.5 [38.3–42.7] | 1,585 32.5 [31.1–33.9] | 833 41.4 [39.2–43.6] |
Kinki | - | 757 15.5 [14.5–16.6] | 342 17.1 [15.4–18.9] | 728 15.2 [14.1–16.3] | 349 17.7 [15.4–18.8] | 757 15.5 [14.5–16.6] | 333 16.5 [14.9–18.3] |
Kyusyu | - | 549 11.3 [10.3–12.2] | 148 7.4 [6.2–8.7] | 553 11.5 [10.6–12.5] | 190 9.3 [8.0–10.7] | 549 11.3 [10.3–12.2] | 177 8.8 [7.5–10.2] |
Shikoku | - | 161 3.3 [2.8–3.9] | 41 2.1 [1.4–2.8] | 142 3.0 [2.5–3.5] | 38 1.9 [1.3–2.6] | 161 3.3 [2.8–3.9] | 37 1.8 [1.2–2.6] |
Tohoku | - | 349 7.2 [6.4–8.0] | 136 6.8 [5.7–8.0] | 355 7.4 [6.6–8.2] | 164 8.0 [6.8–9.3] | 349 7.2 [6.4–8.0] | 168 8.3 [7.1–9.7] |
Abbreviations: CI, confidence interval; JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; NA, not applicable; PMI, Philip Morris International; SD, standard deviation.
*Source: Statistics Bureau of Japan (2015) Source on Education: Statistics Bureau of Japan (2010) Source on Occupation: Public Opinion Survey on the Life of the People (23 June - 10 July 2016).
In each of Y1-Y3, a larger proportion of the sample was based in a major city (Y1-Y3: 27.4%, 28.1%, and 28.6%) than in rural areas (Y1-Y3: 10.0%, 9.3%, and 8.8%). Across Y1-Y3 (Table 1), most of the samples reported high school (Y1-Y3: 49.1%, 50.8%, and 49.8%) or college/university (Y1-Y3: 40.6%, 40.0%, and 41.0%) as the highest level of education, and the most common occupations were homemaker (Y1-Y3: 24.8%, 24.5%, and 24.8%), manual employee (Y1-Y3: 21.8%, 22.8%, and 21.6%), and clerical employee (Y1-Y3: 19.0%, 17.6%, and 17.8%).
JAIQOS samples
Overall, the demographic characteristics of the JAIQOS samples were similar across Y1-Y3 (Table 1). The mean (±SD) ages of the Y1-Y3 samples were 38.5 (±9.7), 39.7 (±10.1), and 39.9 (±9.9) years, respectively, and in each of the samples there were more men (Y1-Y3: 81.6%, 80.3%, and 79.9%) than women (Y1-Y3: 18.4%, 19.7%, and 20.1%).
Across Y1-Y3 (Table 1), most of the participants reported completing college/university (Y1-Y3: 56.8%, 54.4%, and 53.9%) or high school (Y1-Y3: 36.3%, 36.8%, and 37.0%), and the most common occupations were manager (Y1-Y3: 20.7%, 21.1%, and 19.8%) and self-employed/small business owner (Y1-Y3: 16.5%, 17.0%, and 17.6%).
TNP use in JGAP samples
Prevalence of overall TNP use
Across Y1-Y3, the prevalence of overall current (Y1-Y3: 18.5%, 18.9%, 18.2%) former (Y1-Y3: 18.7%, 16.3%, 16.9%), and never (Y1-Y3: 62.9%, 64.8%, 64.9%) TNP use as well as of TNP use by age and sex were similar (Table 2).
Prevalence of individual TNP use
Cigarette smoking prevalence decreased from 17.6% in Y1 to 16.0% in Y3, while the use prevalence of other TNPs, including HTPs and e-cigarettes, increased (Table 3). The use prevalence of all HTP brands (i.e., IQOS™, Ploom/Ploom Tech, and glo) increased across Y1-Y3, and, of all HTP brands surveyed, IQOS had the highest use prevalence (Y1-Y3: 1.8%, 3.2%, 3.3%). The use prevalence of e-cigarettes increased from 0.7% to 1.6% to 2.0% during Y1-Y3.
Number (n) and percentage (% [95% CI]) | ||||
---|---|---|---|---|
Study year* | Cigarettes** | IQOS™ | E-cigarettes | |
Overall | ||||
1 | 852 17.6 [16.5–18.7] | 86 1.8 [1.4–2.2] | 35 0.7 [0.5–1.1] | |
2 | 825 17.3 [16.2–18.5] | 152 3.2 [2.7–3.8] | 76 1.6 [1.2–2.0] | |
3 | 1150 16.0 [15.1–17.0] | 240 3.3 [2.9–3.8] | 146 2.0 [1.7–2.4] | |
Sex | ||||
1 | 654 28.2 [26.3–30.1] | 70 3.0 [2.3–3.8] | 25 1.1 [0.6–1.6] | |
Men | 2 | 630 28.4 [26.5–30.4] | 114 5.1 [4.2–6.2] | 59 2.7 [2.0–3.5] |
3 | 882 26.3 [24.8–27.9] | 181 5.4 [4.6– 6.3] | 104 3.1 [2.5–3.8] | |
1 | 198 7.9 [6.8–9.0] | 16 0.6 [0.3–1.1] | 10 0.4 [0.1–0.8] | |
Women | 2 | 195 7.7 [6.6–8.8] | 38 1.5 [1.0–2.1] | 17 1.1 [0.3–1.1] |
3 | 268 7.0 [6.2–7.9] | 59 1.5 [1.1–2.0] | 42 1.1 [0.7–1.5] | |
Age group (years) | ||||
1 | 98 18.6 [15.3–22.2] | 20 3.8 [2.3–5.8] | 9 1.7 [0.7–3.3] | |
20–29 | 2 | 70 15.1 [11.9–18.8] | 23 5.0 [3.1–7.4] | 14 3.0 [1.6–5.1] |
3 | 108 15.4 [12.8–18.4] | 37 5.3 [3.7–7.3] | 22 3.1 [1.9–4.8] | |
1 | 172 23.9 [20.8–27.2] | 23 3.2 [2.0–4.8] | 6 0.8 [0.3–1.9] | |
30–39 | 2 | 145 21.8 [18.625.2] | 58 8.7 [6.6–11.2] | 16 2.4 [1.3–3.9] |
3 | 196 20.2 [17.7–23.0] | 87 9.0 [7.2–11.0] | 38 3.9 [2.7–5.4] | |
1 | 214 24.6 [21.7–27.7] | 25 2.9 [1.8–4.3] | 9 1.0 [0.4–2.0] | |
40–49 | 2 | 196 22.2 [19.5–25.2] | 36 4.1 [2.8–5.7] | 23 2.6 [1.6–3.9] |
3 | 270 20.4 [18.2–22.7] | 62 4.7 [3.6–6.0] | 37 2.8 [1.9–3.9] | |
1 | 368 13.5 [12.2–14.9] | 18 0.7 [0.3–1.1] | 11 0.4 [0.2–0.8] | |
50+ | 2 | 414 15.0 [13.7–16.5] | 35 1.3 [0.8–1.8] | 23 0.8 [0.5–1.3] |
3 | 576 13.8 [12.7–14.9] | 54 1.3 [0.9–1.7] | 49 1.2 [0.8–1.6] |
In each of Y1-Y3, cigarette smoking was more prevalent among men (Y1-Y3: 28.2%, 28.4%, and 26.3%) than women (Y1-Y3: 7.9%, 7.7%, and 7.0%) and was highest among 40–49-year-olds (Y1-Y3: 24.6%, 22.2%, and 20.4%). The IQOS use prevalence in each of Y1-Y3 was higher among men (Y1-Y3: 3.0%, 5.1%, and 5.4%) than women (Y1-Y3: 0.6%, 1.5%, and 1.5%) and was highest among 20–29-year-olds (3.8%) in Y1, but shifted to be highest among 30–39-year-olds in Y2 (8.7%) and Y3 (9.0%). In both Y1 (1.7%) and Y2 (3.0%), e-cigarette use prevalence was highest among 20–29-year-olds, but in Y3 shifted to be highest among 30–39-year-olds (3.9%; Table 3).
Patterns of TNP use
Across Y1-Y3 (Table 4), exclusive use of only one type of TNP decreased (Y1-Y3: 82.3%, 75.0%, and 70.4%), while dual use of two types of TNPs increased (Y1-Y3: 14.3%, 17.2%, and 16.7%) and poly-TNP use increased markedly (Y1-Y3: 2.1%, 6.1%, and 10.0%).
Number (n) and percentage (% [95% CI]) | |||
---|---|---|---|
Year 1 (2016/2017) (n=887) | Year 2 (2017/2018) (n=900) | Year 3 (2018/2019) (n=1,304) | |
Exclusive use | 730 82.3 [79.6–84.8] | 675 75.0 [72.0–77.8] | 918 70.4 [67.8–72.9] |
Cigarettes* | 705 79.5 [76.6–82.1] | 613 68.1 [64.9–71.2] | 822 63.0 [60.3–65.7] |
IQOS™ | 22 2.5 [1.5–3.8] | 43 4.8 [3.4–6.4] | 69 5.3 [4.1–6.7] |
E-cigarettes | 3 0.3 [0.0–1.0] | 10 1.1 [0.5–2.1] | 6 0.5 [0.1–1.0] |
One other TNP | - | 9 1.0 [0.4–1.9] | 21 1.6 [ 0.9–2.5] |
Dual use | 127 14.3 [12.0–16.8] | 155 17.2 [14.8–19.9] | 218 16.7 [14.7–18.9] |
Cigarettes + other product | 64 7.2 [5.6–9.2] | 72 8.0 [6.3–10.0] | 110 8.4 [6.9–10.1] |
Cigarettes + IQOS | 40 4.5 [3.2–6.1] | 62 6.9 [5.3–8.8] | 62 4.8 [3.6–6.1] |
Cigarettes + e-cigarettes | 13 1.5 [0.7–2.5] | 15 1.7 [0.9–2.8] | 11 0.8 [0.4–1.6] |
IQOS + e-cigarettes | 5.0 0.6 [0.1–1.4] | 4 0.4 [0.1–1.2] | 15 1.2 [0.6–1.9] |
IQOS + other product | 4 0.5 [0.1–1.2] | 2 0.2 [0.0–0.9] | 11 0.8 [0.4–1.6] |
E–cigarettes + other product | 1 0.1 [0.0–0.7] | - | 8 0.6 [0.2–1.3] |
Two other products | – | – | 1 0.1 [0.0–0.5] |
Poly use | 19 2.1 [1.2–3.4] | 55 6.1 [4.6–7.9] | 131 10.0 [8.4–11.9] |
Cigarettes + IQOS + e-cigarettes | 10 1.1 [0.5–2.1] | 16 1.8 [1.0–2.9] | 36 2.8 [1.9–3.9] |
Cigarettes + IQOS + other product(s) | 4 0.5 [0.1–1.2] | 7 0.8 [0.3–1.6] | 18 1.4 [0.8–2.2] |
Cigarettes + e-cigarettes + other product(s) | 3 0.3 [0.0–1.0] | 18 2.0 [1.1–3.2] | 45 3.5 [2.5– 4.6] |
Cigarettes + other products | 2 0.2 [0.0–0.9] | 1 0.1 [0.0–0.7] | 8 0.6 [0.2–1.3] |
Cigarettes + IQOS + e-cigarettes + other product(s) | – | 9 1.0 [0.4–1.9] | 18 1.4 [0.8–2.2] |
IQOS + e-cigarettes + other product(s) | – | 4 0.4 [0.1–1.2] | 5 0.4 [0.1–0.9] |
IQOS + other products | – | – | 1 0.1 [0.0–0.5] |
E-cigarettes + other products | – | – | – |
Three or more other products | – | – | – |
Undefined | 11 1.2 [0.6–2.3] | 15 1.7 [0.9–2.8] | 37 2.8 [2.0–3.9] |
Across Y1-Y3 (Table 4), the greatest proportion, although declining, of participants who reported TNP use were exclusive cigarette smokers (Y1-Y3: 79.5%, 68.1%, and 63.0%), while conversely, the proportion of exclusive IQOSTM users increased (Y1-Y3: 2.5%, 4.8%, and 5.3%), and that of exclusive e-cigarette users remained low (Y1-Y3: 0.3%, 1.1%, and 0.5%).
Frequency and Intensity of TNP use
Among the participants in the JGAP samples in Y1-Y3 who were currently using cigarettes (Y1-Y3: n=852; n=825; and n=1,150), the average number of cigarettes smoked per day (over the last 30 days) appeared to be stable (Y1-Y3: 16.0, 15.7, and 15.5) (Table 5).
Mean [95% CI] | |||
---|---|---|---|
Year 1* | Year 2 | Year 3 | |
Current cigarette smokers — JGAP | (n=852) | (n=825) | (n=1,150) |
Cigarettes smoked per day | |||
Number of days of cigarette smoking in the last 30 days | 29.4 [29.1–29.7] | 29.2 [28.9–29.5] | 29.3 [29.0–29.5] |
Average number of cigarettes smoked per day (based on smoking days only) | 16.2 [15.5–16.8] | 15.9 [15.3–16.6] | 15.8 [15.3–16.3] |
Average number of cigarettes smoked per day in terms of the last 30-day period | 16.0 [15.3–16.6] | 15.7 [15.1–16.4] | 15.5 [14.9–16.0] |
Current IQOS™ users — JAIQOS | (n=2,000) | (n=2,044) | (n=2,013) |
HEETS/HeatSticks used per day | |||
Number of days of IQOS™ use in the last 30 days | 29.1 [28.9–29.3] | 28.9 [28.7–29.1] | 28.8 [28.5–29.0] |
Average number of HEETS/HeatSticks used per day (based on usage days only) | 16.2 [15.8–16.6] | 16.5 [16.1–16.9] | 15.9 [15.5–16.3] |
Average number of HEETS/HeatSticks used per day in terms of the last 30-day period | 15.9 [15.5–16.3] | 16.1 [15.7–16.5] | 15.5 [15.1–15.9] |
TNP initiation/relapse/reinitiation
Among the participants who were never TNP users 12 months prior to the survey (Y1-Y3: n=3,066; n=3,109; and n=4,685), TNP use initiation with cigarettes in the preceding 12 months was considerably higher (Y1-Y3: 0.2%, 0.3%, and 0.2%) than initiation with IQOS™ (Y1-Y3: 0.03%, 0.1%, and 0.1%) (Table 6).
Never TNP Users Number (n) and percentage (% [95% CI]) | |||
---|---|---|---|
Year 1* (n=3,066) | Year 2 (n=3,109) | Year 3 (n=4,685) | |
Initiation with | |||
Cigarettes** | 7 0.2 [0.0–0.5] | 9 0.3 [0.1–0.6] | 10 0.2 [0.1–0.4] |
IQOS™ with HEETS/HeatSticks | 1 0.03 [0.0–0.2] | 4 0.1 [0.0–0.4] | 5 0.1 [0.0–0.3] |
Abbreviations: CI, confidence interval, JAIQOS, sample of adult Japanese IQOS™ users from PMI’s IQOS owner database in Japan; JGAP, representative sample of the Japanese general adult population; NA, not applicable; PMI, Philip Morris International; TNP, tobacco or nicotine-containing product.
*Year 1 (2016/2017), Year 2 (2017/2018), and Year 3 (2018/2019)
** Cigarettes include hand-rolled cigarettes
Note: Initiation with e-cigarettes was not measured as part of the study.
Among current TNP users in Y1-Y3 (Y1-Y3: n=894; n=900; and n=1,304), in each year only one participant reinitiated TNP use with IQOSTM (Y1-Y3: 0.1%, 0.1%, and 0.07%). No relapse to IQOS use was reported in any of the three study years (Table 7).
Current TNP users Number (n) and percentage (% [95% CI]) | |||
---|---|---|---|
Year 1* (n=894) | Year 2 (n=900) | Year 3 (n=1,304) | |
Relapse to IQOS™ | 0 0.0 [0.0–0.5] | 0 0.0 [0.0–0.5] | 0 0.0 [0.0–0.3] |
Reinitiation with IQOS | 1 0.1 [0.0–0.7] | 1 0.1 [0.0–0.7] | 1 0.07 [0.0–0.5] |
TNP use in the JAIQOS samples
Patterns of TNP Use
Across Y1-Y3, a decreasing majority of participants in the samples used IQOSTM exclusively (Y1-Y3: 63.4%, 52.3%, and 49.4%), while the proportion who used IQOS together with other smoke-free TNPs increased (Y1-Y3: 7.6%, 17.7%, and 27.0%) and the proportion who used IQOS together with combustible TNPs decreased (Y1-Y3: 28.4%, 25.4%, and 23.6%). Consequently, by Y3, a greater proportion of participants used IQOS together with other smoke-free TNPs than IQOS together with combustible TNPs (Table 8).
Number (n) and percentage (% [95% CI]) | |||
---|---|---|---|
Year 1* (n=1,946) | Year 2 (n=1,972) | Year 3 (n=1,977) | |
IQOS™ only | 1,234 63.4 [61.2–65.6] | 1,032 52.3 [50.1–54.6] | 976 49.4 [47.1–51.6] |
IQOS + combustible TNP | 552 28.4 [26.3–30.5] | 501 25.4 [23.4–27.4] | 467 23.6 [21.7–25.6] |
IQOS + smoke-free TNP | 148 7.6 [6.4–8.9] | 350 17.7 [16.0–19.6] | 534 27.0 [25.0–29.1] |
Undefined | 12 0.6 [0.3-1.1] | 89 4.5 [3.6-5.6] | 0 |
Abbreviations: CI, confidence interval; JAIQOS, sample of adult Japanese IQOS users from PMI’s IQOS™ owner database in Japan; JGAP, representative sample of the Japanese general adult population; PMI, Philip Morris International; TNP, tobacco or nicotine-containing product.
*Year 1 (2016/2017), Year 2 (2017/2018), and Year 3 (2018/2019)
Frequency and intensity of TNP use
In each of Y1-Y3 (Table 5), the average number of days of IQOSTM use in the last 30 days (Y1-Y3: 29.1, 28.9, and 28.8) and the average number of HEETSTM/HeatSticksTM used on the days of IQOS use in the last 30 days (Y1-Y3: 16.2, 16.5, and 15.9) were relatively stable. Thus, the average daily HEETS/HeatSticks consumption (over the last 30 days) across Y1-Y3 was similarly stable (Y1-Y3: 15.9, 16.1, and 15.5).
History of TNP use
In each of Y1-Y3, the majority of the JAIQOS sample participants had a smoking history before starting IQOSTM use (Y1-Y3: 98.0%, 98.7%, and 99.3%), while only a few were never smokers (Y1-Y3: 2.0%, 1.3%, and 0.7%) before starting IQOS use.
The present study is the first to report data on the prevalence and patterns of TNP use in samples of the Japanese general adult population (JGAP) and samples of Japanese adult IQOS users (JAIQOS) over the same three consecutive years (2016/2017, 2017/2018, and 2018/2019). The findings of this study are consistent with the trends observed by other surveys that have examined the prevalence and patterns of TNP use since the introduction of the HTP IQOSTM in Japan in 201427–31.
In the JGAP samples, the prevalence of overall TNP use was stable (~18%) across the study years. However, there was a trend towards a declining prevalence of cigarette smoking concurrent with an increase in smoke-free TNP and total HTP use, especially in the case of IQOSTM use (from 1.8% in 2016/2017 to 3.3% in 2018/2019).
It can, therefore, be concluded that the introduction of smoke-free TNPs does not lead to an unintended increase in overall TNP use in the general population, but rather drives a shift in TNP use patterns from cigarettes to smoke-free TNPs. When considered alongside the low TNP initiation rates with IQOSTM, the present findings further imply that introduction of smoke-free TNPs does not lead to an unintended increase in TNP use among non-users. This hypothesis is partially supported by the findings of other studies32,33 and is consistent with the findings of Cummings et al.4, who reported an accelerated reduction in cigarette sales in Japan concurrent with the introduction and increase in HTP sales. In agreement with Cummings et al.4 and others30,31, the total HTP use prevalence in year 3 of the present study was over 5%. A previous study had reported a total HTP use prevalence of 11%34. The prevalence of cigarette smoking observed in each year of the present study was in agreement with the prevalence data from the Japan National Health and Nutrition Survey for 2017 (18.8%)27, 2018 (18.9%)28, and 2019 (17.7%)29. Additionally, the present cigarette and overall TNP use data were well in line with those from other contemporaneous surveys30,31,35,36. Tabuchi et al.32 reported an IQOS use prevalence of 3.6% in 2017, which is higher than that observed in the present study (1.8%) for the same year. For 2018, Sutanto et al.37 reported an any-brand HTP use prevalence (i.e., IQOS, glo, and Ploom/Ploom Tech) of 2.7%, which is less than that observed in our study (3.2%) for IQOS use alone. These discrepancies are likely due to methodological differences (i.e., cross-sectional vs. longitudinal design or in-person vs. online interview) as described previously23.
In the JAIQOS samples, the age and sex distribution observed in each study year as well as the current HTP use patterns are in line with the Japan National Health and Nutrition Survey results for the same years27–29. Similarly, in agreement with the Japanese national survey27–29, the results presented here indicate that the majority of HTP users are using HTP exclusively. The average number of HEETSTM/HeatSticksTM used per day (Y1-Y3: 15.9, 16.1, and 15.5, respectively) in the JAIQOS samples was relatively stable across the study years and comparable with the 14.3 HEETS/HeatSticks used per day reported in Japan by Jones et al.31 in 2019. Moreover, the HEETS/HeatSticks consumption per day in the JAIQOS samples was very close to the average number of cigarettes consumed per day (Y1-Y3: 16.0, 15.7, and 15.5, respectively) among cigarette smokers in the JGAP samples, suggesting that IQOS users are not increasing their daily consumption upon switching from cigarettes to IQOS.
TNP initiation, relapse, and reinitiation rates observed with IQOSTM in the present study were relatively low in all three years, indicating that IQOS uptake was limited to existing smokers who had switched to IQOS. Similarly, Sutanto et al.37 concluded that “virtually all HTP users were current cigarette smokers (67.8%) or former smokers (25.0%); and that only 1.0% of HTP users were never smokers.” Jones et al.31 observed that HTP uptake in 2019 occurred “almost exclusively among current tobacco users in Japan, with negligible uptake among never tobacco users.” In both samples in the present study, nearly all current IQOS users had started TNP use with cigarette smoking. These findings suggest that IQOS uptake is occurring among current adult smokers, which is in alignment with both the principles of harm reduction and the United States Food and Drug Administration’s (FDA) conclusion that IQOS has “potential benefit to population health.”20
Major strengths of this study, among those previously described23, include the annual repeated data collection using the same sampling framework and methods, face-to-face interviews, and nationally representative samples. The limitations of the current study include all biases typically associated with self-reported measures, such as recall, social desirability, or response bias as well as sampling and selection bias. To overcome these limitations, particularly in the JAIQOS sample, the response rates were monitored and compared against preestablished quotas on the basis of age and sex.
While cigarette smoking remains the most prevalent way of consuming TNPs in Japan, a significant and growing number of adult Japanese smokers have switched to smoke-free alternatives such as IQOSTM, with the majority using these products exclusively. Additionally, there has been low initiation with IQOS among TNP never and former users. Taken together, the findings of the present study on the prevalence and patterns of IQOS use indicate that IQOS use behavior trends are in line with the principles of tobacco harm reduction and that HTPs are effective tools for complementing current tobacco control efforts14.
INTERVALS: YEAR 1–3 DATA (SAS DATASETS, CC-BY 4.0), https://doi.org/10.26126/intervals.r35iml.138
This project contains the following underlying data:
▪ SAS datafiles in the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM) structure (www.cdisc.org/standards) for each of the study years 1–3.
○ The ADSL (adsl_y1_jp.sas7bdat, adsl_y2_jp.sas7bdat, and adsl_y3_jp.sas7bdat,) datasets are the Subject Level Analysis Datasets and contain the main information on participants identifier, demographics, and tobacco and/or nicotine product use groups and patterns to facilitate analysis and interpretation of analysis.
○ The ADQS (adqs_y1_jp.sas7bdat, adqs_y2_jp.sas7bdat, and adqs_y3_jp.sas7bdat) datasets are the Questionnaire Analysis Datasets and contain specific information on the study survey, i.e., all questions and items answered by participants in the survey.
○ The ADEX (adex_y1_jp.sas7bdat, adex_y2_jp.sas7bdat, and adex_y3_jp.sas7bdat) datasets are the Exposure Analysis Datasets and contain specific information on the TNP use exposure, i.e., all questions and items answered by participants in the survey related to their product use.
○ The ADAM Metadata Files (ADaM_PMX01JP_AnY1_Metadata, ADaM_PMX01JP_AnY2_Metadata, and ADaM_PMX01JP_AnY3_Metadata) contain the datasets and variable labels and definitions, code lists to decode the variables names, terms and values, and the methods and computational algorithms to derive the analytical datasets.
▪ Study Year 1 Data and Metadata: https://doi.org/10.26126/intervals.8ybcxu
▪ Study Year 2 Data and Metadata: https://doi.org/10.26126/intervals.hxaf2v
▪ Study Year 3 Data and Metadata: https://doi.org/10.26126/intervals.6jbifs
INTERVALS: Tobacco Use Prevalence Questionnaire. https://doi.org/10.26126/intervals.rxhx4a.138
This project contains the following extended data:
▪ Tobacco Use Prevalence questionnaire (Tobacco Use Prevalence Questionnaire_engl_jap.pdf) is the questionnaire administered in the general population and IQOS user surveys (English and Japanese version).
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
This study followed the STROBE reporting guideline.
INTERVALS: STROBE checklist and flow chart for “Trends in Prevalence and Patterns of Use of a Heated Tobacco Product (IQOS™) in Japan: A 3-Year Repeated Cross-Sectional Study”, are available: https://doi.org/10.26126/intervals.dluspw
The authors would like to thank all those who participated in this study. The authors also would like to thank Antonio Ramazzotti for reviewing and providing insightful comments on this publication.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
No
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Modelling and empirical analyses
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: The reviewers are employees of Altria Client Services LLC (ALCS). Philip Morris USA Inc., which is an affiliate of ALCS, has distributed and sold iQOS® heated tobacco products in the U.S. This research was funded by Philip Morris International Inc., which is an independent entity not affiliated with ALCS or Philip Morris USA Inc.. This potential conflict of interest did not impact the impartiality of our review, which was conducted to assess the scientific merit of the research regardless of the source of funding or author affiliations.
Reviewer Expertise: Tobacco regulatory science.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (revision) 21 Nov 22 |
read | read | |
Version 1 30 Jun 22 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)